Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VBI Vaccines Inc.    VBIV   CA91822J1030

VBI VACCINES INC.

(VBIV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société VBI VACCINES INC.
08:10aVBI VACCINES : Announces Submission of Biologics License Application to FDA for ..
BU
11/23VBI VACCINES : Announces Submission of Marketing Authorization Application for 3..
BU
11/19VBI-1901 : SNO Phase 2a Data & Clinical Update
PU
11/19VBI VACCINES : Announces Positive Interim Phase 2a Data from VBI-1901 in Recurre..
BU
11/18VBI VACCINES : Announces Positive Interim Phase 1b/2a Data for Hepatitis B Immun..
BU
11/13VBI VACCINES : Phase 3 Sci-B-Vac® Data at The Liver Meeting® 2020
PU
11/13VBI VACCINES : Presents Phase 3 Sci-B-Vac® Data at The Liver Meeting® 2020
BU
11/09VBI VACCINES : Announces e-Poster Presentation at the Society for Neuro-Oncology..
BU
10/26VBI VACCINES : Presents Phase 3 Sci-B-Vac® Data at ID Week 2020™
BU
10/15VBI VACCINES : to Present at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Co..
BU
10/08VBI VACCINES : Announces e-Poster Presentation at The Liver Meeting® 2020
BU
09/24VBI VACCINES : to Present at Upcoming Scientific Conferences
BU
09/17VBI VACCINES : Announces Biomarker Data From VBI-1901 Phase 1/2a Study in Recurr..
BU
09/14VBI VACCINES : to Present Additional Biomarker Data from VBI-1901 Phase 1/2a Stu..
BU
08/31VBI VACCINES : Sci-B-Vac® Phase 3 Data at EASL 2020
PU
08/31VBI VACCINES : Presents Phase 3 Sci-B-Vac® Data at EASL 2020
BU
08/26VBI VACCINES :  VBI Vaccines Announces Preclinical Coronavirus Program Data and ..
BU
08/20VBI VACCINES : Announces Multiple Phase 3 Sci-B-Vac® Abstracts Accepted for Oral..
BU
08/05VBI VACCINES : Awarded Up to CAD$56 Million Contribution from Canadian Governmen..
BU
07/31VBI VACCINES : Announces Second Quarter 2020 Financial Results and Provides Corp..
BU
07/20VBI VACCINES : Thinking about buying stock in Tonix Pharmaceuticals, Heat Biolog..
PR
06/22VBI-1901 : AACR Data, Partial Response and Biomarker Strategy
PU
06/22VBI-1901 : AACR Data and Clinical Update
PU
06/22VBI VACCINES ANNOUNCES DATA FROM VBI : Partial Response Observed, Promising Biom..
BU
06/18VBI VACCINES : Announces Results of Annual General Meeting
BU
06/17VBI VACCINES : to Present at Upcoming Investor Conferences
BU
05/28VBI VACCINES : Announces Formation of Commercial Advisory Board
BU
05/27VBI VACCINES : Secures $50 Million Debt Financing From K2 HealthVentures
BU
05/21VBI-2901 : Pan-Coronavirus Vaccine Candidate Overview
PU
05/15VBI VACCINES : Announces Upcoming Poster Presentation of Phase 1/2a data of VBI-..
BU
05/06VBI VACCINES : Announces First Quarter 2020 Financial Results and Provides Corpo..
PU
05/06VBI VACCINES : Announces First Quarter 2020 Financial Results and Provides Corpo..
BU
04/27VBI VACCINES : Announces Closing of Public Offering of Common Stock and Full Exe..
BU
04/22VBI VACCINES : Announces Pricing of $50 Million Public Offering
BU
04/21VBI VACCINES : Announces Proposed Public Offering of Common Shares
BU
03/31VBI VACCINES : Announces Collaboration with the National Research Council of Can..
BU
03/12VBI VACCINES : Appoints Damian Braga to Board of Directors
BU
03/05VBI VACCINES : Provides Corporate Update, Outlook for 2020, and Year-End 2019 Fi..
BU
03/03VBI VACCINES : Provides Update on Part A of Ongoing Phase 1/2a Study Demonstrati..
BU
03/02VBI VACCINES : Announces Dosing of First Recurrent GBM Patient in Phase 2a Study..
BU
01/14VBI VACCINES : Regains Compliance with Nasdaq Minimum Bid Price Requirement
BU
01/09VBI VACCINES : Announces Second Pivotal Phase 3 Study of Sci-B-Vac® Meets Primar..
BU
2019VBI VACCINES : Presents Early GBM Tumor Response and Immunologic Data from Part ..
PU
2019VBI VACCINES : Presents Early GBM Tumor Response and Immunologic Data from Part ..
BU
2019VBI VACCINES : and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-..
BU
2019VBI VACCINES : to Present Initial Phase 1/2a Part B Data of VBI-1901 at the 2019..
BU
2019VBI VACCINES : Announces Third Quarter 2019 Financial Results and Provides Corpo..
BU
2019VBI VACCINES : to Present New Immuno-Oncology Data at the World Vaccine Congress..
BU
2019VBI VACCINES : Announces Late-Breaker Poster Presentation at The Liver Meeting® ..
BU
2019VBI VACCINES : Announces Late-Breaker Oral Presentation at IDWeek 2019™
BU
2019VBI VACCINES : Announces Closing of Public Offering of Common Stock and Full Exe..
BU
2019VBI VACCINES : Announces Pricing of $35 Million Public Offering
BU
2019VBI VACCINES : Announces Proposed Public Offering of Common Shares
BU
2019VBI VACCINES : Announces Phase 2a Clinical Evaluation of VBI-1901 Cancer Vaccine..
BU
2019VBI Vaccines Announces Second Quarter 2019 Financial Results and Provides Cor..
GL
2019VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ong..
GL
2019VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes
GL
2019VBI Vaccines to Present at the BMO Capital Markets 2019 Prescriptions for Suc..
GL
2019VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phas..
GL
2019VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clini..
GL
2019VBI Vaccines Announces Results of Annual General Meeting
GL
2019VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-..
GL
2019VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Developm..
GL
2019VBI Vaccines Appoints Joanne Cordeiro to Board of Directors
GL
2019VBI Vaccines to Present at the Oppenheimer 29th Annual Healthcare Conference
GL
2019VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 F..
GL
2018VBI Vaccines Announces Closing of Public Offering of Common Stock and Partial..
GL
2018VBI Vaccines Announces Pricing of $37.5 Million Public Offering
GL
2018VBI Vaccines Announces Proposed Public Offering of Common Shares
GL
2018VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (..
GL
2018VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI..
GL
2018VBI Vaccines Responds to Unfounded Allegations in Globes Article
GL
2018VBI Vaccines to Present at the 20th Annual Rodman & Renshaw Global Investment..
GL
2018VBI Vaccines Appoints Christopher McNulty as Chief Financial Officer and Head..
GL
2018VBI Vaccines Announces Second Quarter 2018 Financial Results and Provides Cor..
GL
1  2Next
Upcoming event on VBI VACCINES INC.